February 2021 Volume 19, Issue 2, Supplement 7 A SPECIAL MEETING REVIEW EDITION Highlights in Hodgkin Lymphoma From the 62nd American Society of Hematology Annual Meeting and Exposition A Review of Selected Presentations From the All-Virtual 62nd ASH Meeting and Exposition • December 5-8, 2020 Special Reporting on: • Frontline Brentuximab Vedotin as Monotherapy or in Combination for Older Hodgkin Lymphoma Patients • Phase II Study of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma • Consolidation With Nivolumab and Brentuximab Vedotin After Autologous Hematopoietic Cell Transplantation in Patients With High-Risk Hodgkin Lymphoma • Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine- Based Antibody-Drug Conjugate, in Patients With Relapsed or Refractory Hodgkin Lymphoma • Brentuximab Vedotin With Chemotherapy for Patients With Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study • Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Phase I/II Investigator Initiated Trial (EVITA Study) • PET-Guided Strategy Improves the Safety of BEACOPP-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa AHL 2011 Phase 3 Study • Survival Outcomes for US and Canadian Patients Diagnosed With Hodgkin Lymphoma Before and After Brentuximab Vedotin Approval for Relapsed/Refractory Disease: A Retrospective Cohort Study PLUS Meeting Abstract Summaries With Expert Commentary by: Andrew M. Evens, DO, MSc, FACP Professor of Medicine, Rutgers Robert Wood Johnson Medical School Associate Director for Clinical Services, Rutgers Cancer Institute of New Jersey Director, Lymphoma Program, Division of Blood Disorders Medical Director, Oncology Service Line, RWJBarnabas Health New Brunswick, New Jersey ON THE WEB: hematologyandoncology.net Indexed through the National Library of Medicine (PubMed/MEDLINE), PubMed Central (PMC), and EMBASE EDITORIAL ADVISORY BOARD Lee Schwartzberg, MD Steven M. Horwitz, MD Claire Harrison, MD, FRCP The West Clinic Memorial Sloan Kettering Guy’s and St Thomas’ Hospital Editors-in-Chief Cancer Center George W. Sledge Jr, MD John O. Mascarenhas, MD Richard R. Furman, MD Stanford University Brad S. Kahl, MD Mount Sinai Medical Center Weill Cornell Medicine Washington University NewYork-Presbyterian COLORECTAL CANCER School of Medicine Ruben A. Mesa, MD Hospital Tanios S. Bekaii-Saab, MD UT Health San Antonio Mayo Clinic John P. Leonard, MD Cancer Center Daniel J. George, MD Weill Cornell Medicine Duke University Medical Center Edward Chu, MD NewYork-Presbyterian Hospital Srdan Verstovsek, MD, PhD UPMC Hillman Cancer Center MD Anderson Cancer Center Section Editors University of Pittsburgh Craig H. Moskowitz, MD University of Miami NEUTROPENIA Melanoma in Focus David H. Ilson, MD, PhD Sylvester Comprehensive Cancer Center David C. Dale, MD Sanjiv S. Agarwala, MD Memorial Sloan Kettering Cancer University of Washington St Luke’s Cancer Center and Center John M. Pagel, MD, PhD Temple University John L. Marshall, MD Swedish Cancer Institute OVARIAN CANCER Maurie Markman, MD Prostate Cancer in Focus Georgetown University Hospital MELANOMA Cancer Treatment Centers Andrew J. Armstrong, MD Mohamed E. Salem, MD John M. Kirkwood, MD of America Duke University Medical Center Carolinas Medical Center University of Pittsburgh Cancer Institute PANCREATIC CANCER Ovarian Cancer in Focus Leonard Saltz, MD Margaret Tempero, MD Robert L. Coleman, MD Memorial Sloan Kettering MULTIPLE MYELOMA University of California, US Oncology Network Cancer Center Kenneth C. Anderson, MD San Francisco Comprehensive Dana-Farber Cancer Institute Cancer Center Colorectal Cancer in Focus ENDOCRINE CANCER Axel Grothey, MD Alexandria Phan, MD James R. Berenson, MD PEDIATRIC HEM/ONC West Cancer Center UT Health North Campus Tyler Institute for Myeloma University of Tennessee Mitchell S. Cairo, MD MD Anderson Cancer Center & Bone Cancer Research New York Medical College Hematology Sundar Jagannath, MD HEAD AND NECK CANCER PROSTATE CANCER Craig M. Kessler, MD Mount Sinai Medical Center Georgetown University Marshall R. Posner, MD David B. Agus, MD Mount Sinai Medical Center Medical School Ola Landgren, MD University of Southern California Lombardi Comprehensive Sylvester Comprehensive Cancer Keck School of Medicine Cancer Center KIDNEY CANCER Center Robert A. Figlin, MD Michael A. Carducci, MD Lung Cancer in Focus Cedars-Sinai Comprehensive Paul G. Richardson, MD The Sidney Kimmel Edward S. Kim, MD Cancer Center Dana-Farber Cancer Comprehensive Cancer Center City of Hope Institute at Johns Hopkins Brian I. Rini, MD Hematologic Malignancies Vanderbilt University Medical Center MYELOPROLIFERATIVE SARCOMAS/GISTs Susan O’Brien, MD NEOPLASMS George D. Demetri, MD University of California, Irvine LEUKEMIA Guillermo Garcia-Manero, MD Dana-Farber Cancer Institute Jan A. Burger, MD, PhD MD Anderson Cancer Center Drug Development MD Anderson Cancer Center Mark J. Ratain, MD The University of Chicago Elihu H. Estey, MD Fred Hutchinson Cancer Center Breast Cancer in Focus Hope S. Rugo, MD Elias Jabbour, MD UCSF Helen Diller Family MD Anderson Cancer Center Comprehensive Cancer Center Hagop M. Kantarjian, MD Founding Editor MD Anderson Cancer Center Bruce D. Cheson, MD Georgetown University Hospital Neil E. Kay, MD CEO and Copublisher Lombardi Comprehensive Mayo Clinic, Rochester Steven H. Kurlander Cancer Center LUNG CANCER President and Copublisher Jeffrey Crawford, MD Paul H. McDaniel Duke University Medical Center aHUS, TTP Editorial Director David S. Ettinger, MD Jeffrey C. Laurence, MD The Sidney Kimmel Devon Schuyler Weill Cornell Medicine Comprehensive Cancer Center NewYork-Presbyterian at Johns Hopkins Contributing Editor Hospital Jacquelyn Matos Roy S. Herbst, MD, PhD BREAST CANCER Yale Cancer Center Howard A. Burris III, MD Art Director The Sarah Cannon David H. Johnson, MD Tim Jeffs Cancer Center Southwestern Medical Center William Gradishar, MD Corey J. Langer, MD, FACP Indexed in PubMed/MEDLINE and EMBASE Northwestern University University of Pennsylvania Kathy D. Miller, MD Postmaster: Please send address changes (form 3579) to Clinical LYMPHOMA Indiana University Advances in Hematology & Oncology c/o DMD, 10255 West School of Medicine George P. Canellos, MD Higgins Road, Suite 280, Rosemont, IL 60018. Dana-Farber Cancer Institute Ruth O’Regan, MD ISSN: 1543-0790 University of Wisconsin Andre Goy, MD Carbone Cancer Center Hackensack University Medical Center US-BVP-20-398-MT_111101558-31_Adcetris_FcHL Pro 5 Year Journal_Pg 4CB + 4CB Standard Spread + 3 Pg B/W BS__CAHO Colors: 4CP Bleed/Trim/Live/Fold - DO NOT PRINT Standard Spread Bleed: 16.5 " w x 11.125" h Trim: 16.25" w x 10.875" h Live: 15.75" w x 10.375" h Standard Page Bleed: 8.375 w x 11.125 h Trim: 8.125 w x 10.875 h Live: 7.625 w x 10.375 h Output @ 100% Evoke Giant ECHELON-1 TRIAL cHL 5-YEAR DATA UPDATE STAGE III/IV LASTING REMISSION THE FIRST TIME AROUND Consistent benefit at 5 years vs ABVD Get a snapshot of the 5-year data on the following pages • Primary endpoint: modifi ed PFS per IRF—HR: 0.77 (95% CI: 0.60, 0.98); 1 Warnings and Precautions P = 0.035; median follow-up: 24.6 months • Peripheral neuropathy (PN): ADCETRIS causes PN that is • Prespecifi ed exploratory endpoint: PFS per INV at 5 years—HR: 0.68 (95% CI: predominantly sensory. Cases of motor PN have also been reported. 0.53, 0.87); not in approved labeling; supportive clinical information only2 ADCETRIS-induced PN is cumulative. Monitor for symptoms ECHELON-1 trial design: A randomized, open-label trial of ADCETRIS+AVD such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a vs ABVD in 1334 adult patients with newly diagnosed Stage III/IV cHL. Primary burning sensation, neuropathic pain, or weakness. Institute dose endpoint was modifi ed PFS per IRF, defi ned as progression, death due to any modifi cations accordingly. cause, or receipt of additional anticancer therapy for patients not in complete • Anaphylaxis and infusion reactions: Infusion-related reactions (IRR), remission after fi rst-line therapy. Key secondary endpoint was OS. Prespecifi ed including anaphylaxis, have occurred with ADCETRIS. Monitor patients exploratory endpoint was 5-year PFS per INV, defi ned as progression or death during infusion. If an IRR occurs, interrupt the infusion and institute due to any cause.2,3 appropriate medical management. If anaphylaxis occurs, immediately Indication and permanently discontinue the infusion and administer appropriate ADCETRIS is indicated for the treatment of adult patients with previously medical therapy. Premedicate patients with a prior IRR before subsequent infusions. Premedication may include acetaminophen, untreated Stage III/IV classical Hodgkin lymphoma (cHL) in combination an antihistamine, and a corticosteroid. with doxorubicin, vinblastine, and dacarbazine. Select Important Safety Information Please see additional Important Safety Information and BOXED WARNING Brief Summary of Prescribing Information, including PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): BOXED WARNING, on the following pages. Full JC virus infection resulting in PML and death can occur in Prescribing Information is available at adcetrispro.com ADCETRIS-treated patients. Contraindication ADCETRIS concomitant with bleomycin due to pulmonary toxicity (e.g., interstitial infi ltration and/or infl